Abstract. Tumor progression can be affected by various cellular components of tumor cells and/or by tumor microenvironmental factors. The tumor microenvironment comprises a variety of nonmalignant stromal cells and inflammatory cytokines, which are pivotal in tumor promotion and progression. The transforming growth factor-β (TGF-β) ligands (TGF-β1, 2 and 3) are secreted inflammatory cytokines, which are known to be involved in various aspects of tumor development through two transmembrane serine-threonine kinase receptors, TGFβR1 and TGFβR2. TGF-β promotes or inhibits tumorigenesis depending on the concurrent gene mutations and tissue microenvironment present through the small mothers against decapentaplegic (Smad) and non-Smad pathways. This review aims to provide a comprehensive overview of the role of the TGF-β pathway in tumor initiation and progression.
Introduction
Transforming growth factor-β (TGF-β) signaling forms a complex web in the progression of cancer. There is substantial evidence indicating that downregulated TGF-β signaling in tumor initiation. However, in certain tumors, TGF-β appears to have the ability to exert a tumor-promoting effect depending on cellular context (1) (2) (3) . Accordingly, TGF-β signaling has been considered as a tumor suppressor and a promoter of tumor progression (4, 5) . It acts as a tumor suppressor by inhibiting cell proliferation through repressing the expression of c-Myc and certain cyclin-depenent kinase inhibitors (CDKIs) and through the secretion of anti-angiogenic factors (6, 7) . It functions as a tumor promoter through the stimulation of matrix deposition, perturbation of immune function and induction of epithelial-mesenchymal transition (EMT) (8) . The TGF-β super-family is a large group of structurally associated proteins including TGF-β, nodal, activin, lefty, bone morphogenetic proteins and growth and differentiation factor. There are numerous cellular context-dependent factors tightly implicated in the balance of TGF-β signaling, thus TGF-β signaling forms a complicated network in cancer cells (5).
TGF-β signaling pathways
TGF-β signaling is transduced through Smad and non-Smad pathways. These pathways are mediated by TGF-β ligands, type1 and type2 receptors and Smad or non-Smad proteins, including Akt, extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK; Fig. 1 ). In mammals, there are three types of TGF-β (TGF-β1, 2 and 3), which are encoded by different genes and which function through the same receptor signaling systems (9) . Of these, TGF-β1 is most frequently upregulated in tumor cells (10, 11) . However, the fate of cells following TGF-β1 treatment is often determined by cellular context and experimental conditions (12) (13) (14) .
The TGF-β protein is produced as an inactive 'latent' high weight complex (14) and can be activated through the activity of plasminogen, which preferentially degrades the TGF-β prosegments (15, 16) and through its conformational change by the metalloproteinases, matrix metalloproteinase (MMP)-9 and MMP-2 (17) . There are other activation mechanisms. For example, the extracellular matrix protein, thrombospondin (18, 19) and αvβ6 integrin can regulate the activity of TGF-β through a conformational change (20) . Taken together, tumor cells are well equipped to activate TGF-β locally.
The effects of TGF-β signaling are mediated by three TGF-β ligands (TGF-β1-3) through TGF-β type1 (TGFβR1) and type2 receptors TGFβR2 (21) (22) (23) . TGFβR1 recruits and phosphorylates receptor-regulated Smads (R-Smads) when phosphorylated. TGF-β ligands can bind to TGFβR2 with high affinity once activated by metalloproteinases. Binding of the ligands causes the formation of a heterotetrameric active receptor complex, which results in the phosphorylation of TGFβR1 by TGFβR2. The phosphorylation of R-Smads by TGFβR1 form heteromeric complexes with the common partner Smad (co-Smad; Smad4 in mammals) (17) and these R-Smads-co-Smad complexes translocate into the nucleus to regulate the expression of target genes with other DNA-binding transcription factors.
TGF-β can also activate non-canonical signaling pathways, also termed non-Smad pathways. For example, TGF-β1 is known to activate the Erk/MAPK (24, 25) pathway and the phosphoinositide 3-kinase (PI3K)/Akt (26-28) pathway. These non-Smad pathways work independently or together with Smad complexes to regulate the functions of TGF-β. For example, the activation of Akt signaling by TGF-β1 has been shown to promote cell proliferation (28) . TGF-β receptors activate MMPs, p38MAPK and Zinc finger E-box-binding homeobox 1 (ZEB1), ZEB2, Snail and Slug, leading to EMT, which is required for cancer cell invasion and metastasis. TGF-β can also regulate target gene expression through the MAPK signaling pathway (29, 30 ).
TGF-β and cell proliferation
TGF-β can regulate cell growth, apoptosis, differentiation and fibrosis (1) . There is substantial evidence suggesting that TGF-β can inhibit the proliferation of normal epithelial cells (31, 32) . TGF-β signaling has been reported to mediate cell-cycle progression inpancreatic β-cells by regulating the nuclear localization of CDKI, p27 (31) . TGF-β signaling has also been reported to inhibit the proliferation of tumor cells in certain cases. The findings of a study by Senturk et al suggested that TGF-β induced p53-independent and p16 (Ink4a)-independent and reactive oxygen species (ROS)-dependent, senescence in hepatocellular carcinoma (HCC) cells and inhibited tumor growth (32) . TGF-β was also reported to mediate galangin-induced autophagy. The induction of autophagy reflected the anti-proliferation effect of TGF-β signaling on HCC cells (33) . Certain drugs, including Akbu-LAAO, an L-amino acid oxidase with apparent antibacterial activities, inhibits the growth and induces the apoptosis of HepG2 cells via the TGF-β signaling pathway (34) . By contrast, TGF-β signaling may have a completely different role in cell growth. A previous study demonstrated that TGF-β1 induced the activation of Akt to promote β-catenin nuclear accumulation, which then regulated cyclin D1/c-myc gene transcription to eventually promote mouse precartilaginous stem cell proliferation (35).
TGF-β signaling is involved in the regulation of epithelial-mesenchymal transition
EMT is a key step in the progression of cancer invasion and metastasis, characterized by reduced epithelial marker and elevated mesenchymal marker expression (36, 37) . The EMT process is often associated with upregulation of TGF-β signaling and TGF-β drives EMT through the Smad-mediated or non-Smad-mediated reprogramming of gene expression (Fig. 2) (38) . TGF-β receptors can induce the expression of ZEB1, ZEB2, Snail and Slug through the Smad pathway and mediate MMPs and p38MAPK through non-Smad pathways, which both lead to EMT (39) . ROS are also important in TGF-β-induced EMT, primarily through the activation of MAPK and through subsequent ERK-directed activation of the Smad pathway in proximal tubular epithelial cells (40) . TGF-β signaling not only mediates EMT, but it is also required for distant metastases. A previous study demonstrated that TGF-β in the breast cancer microenvironment promoted pulmonary metastases of breast cancer cells (41).
TGF-β and cancer stem cells
Advances in cancer stem cell (CSC) research have indicated that the TGF-β signaling pathway is essential for the maintenance of CSCs. CSCs have been reported to be responsible for the recurrence of disease following anticancer therapy (42) . Certain extracellular and intracellular signals allow cancer progenitors to dynamically revert to a stem cell state. Evidence has shown that TGF-β induced the expression of CD133, a CSC marker, in liver cancer cell lines and increased tumor initiating ability in mice, compared with the milder and transient effect of interleukin-6 (43). Chanmee et al found that the over production of hyaluronan allowed cancer progenitors to revert to stem cell states via Twist and the TGF-β-Snail signaling axis (44) . Furthermore, tumor-associated macrophages (TAMs) in the tumor microenvironment promoted CSC-like properties via TGF-β1-induced EMT in HCC (45) . MicroRNA (miR)-106b is significantly upregulated in CD44(+) cells and the inhibition of miR-106b shows suppression of the TGF-β/Smad signaling pathway and decreases self-renewal capacity and cell invasiveness (46) . These findings suggest that TGF-β signaling is associated with cancer cell stemness.
There are epigenetic differences in TGF-β signaling-related genes between cancer stem-like cells and differentiated cancer cells. It was previously reported that the methylation levels of genes coding TGF-β signaling-related proteins can regulate breast cancer stem cell differentiation (47) . Evidence suggests that several members of the TGF-β pathway are targeted by long non-coding RNAs, key epigenetic mediators and this may, at least in part, explain the association between cancer cell stemness and TGF-β signaling (48) . These findings may assist in the development of novel agents, which can specifically control increases and decreases in the TGF-β signaling pathway in CSCs and thereby provide a novel avenue for the prevention and treatment of malignant cancer (48).
Crosstalk between TGF-β signaling and inflammation
Acute inflammation is an essential component of the wound-healing response to stimuli. However, chronic inflammation favors the accumulation of mutations and epigenetic aberrations in normal cells, thereby promoting malignant transformation (49, 50) . This process is mediated by chemokines, cytokines and growth factors secreted by stromal components of the tumor microenvironment. Among those secreted factors, the TGF-β subfamily has been shown to generate a favorable immune microenvironment for tumor growth. TGF-β can impair anticancer immune responses in several ways, including immune cell inhibition and the elimination of major histocompatibility complex class I and II (51) . It can also induce TAMs and generate ROS with genotoxic activity (52) (53) (54) . TAMs are primarily a macrophage subpopulation with an M2 phenotype. TAM-derived factors may enhance the invasiveness of tumor cells by enhancing their adhesion to extracellular matrix in the tumor stroma (55, 56) . Evidence from clinical and epidemiological studies has shown that TAM density is positively associated with poor survival rates in several types of cancer (56, 57) . The involvement of ROS signaling in tumor progression has also been recognized (58, 59) . Previous studies have suggested that the increased generation of ROS in tumor cells may affect certain redox-sensitive molecules, leading to mutations and genetic instability, cellular proliferation and metastasis (60,61). Figure 1 . TGF-β transduces signaling through the Smad and non-Smad signaling pathways. In the Smad pathway (left), TGF-β binds to TβRII, which phosphorylates TβRI, which activates Smad2 and Smad3 (R-Smads). Activated Smad2/3 forms R-Smads-co-Smad complexes with Smad4 (co-Smad), which interact with various transcription factors and transcriptional co-activators and regulates the transcription of target genes. TGF-β induces EMT through non-Smad proteins, including ZEB1/ZEB2 and Snail/Slug through the Smad pathway. In the non-Smad pathway (right), TGF-β can mediate EMT through non-Smad pathways. EMT is also mediated by extracellular signaling proteins, including Wnt, Notch ligands and PDGF. TGF-β can regulate other cellular responses with the exception of EMT, through non-Smad pathways, for example the PI3K-Akt signaling pathway and MAPK signaling. TGF-β, transforming growth factor-β; TβR, TGF-β receptor; Smad, small mothers against decapentaplegic; EMT, epithelial-mesenchymal transition; ZEB1, Zinc finger E-box-binding homeobox 1; ZEB2 Zinc finger E-box-binding homeobox 2; PDGF, platelet-derived growth factor; FGF, fibroblast growth factor; PI3K, phosphoinositide 3-kinase; MAPK, mitogen-activated protein kinase; ROS, reactive oxygen species; MMPs, matrix metalloproteinases. Figure 2 . TGF-β drives EMT phenotype. Exposure of tumor cells to TGF-β in situ causes certain cells to become motile and invade into neighboring blood vessels and tissues. This is accompanied by morphogenetic changes. TGF-β, transforming growth factor-β; EMT, epithelial-mesenchymal transition.
TGF-β signaling in the regulation of tumor angiogenesis
The ability of tumor cells to induce the formation of blood vessels is crucial for tumor growth, invasion and metastasis. TGF-β is a key mediator of angiogenesis in the tumor microenvironment, contributing to angiogenesis by inducing proangiogenic factors (62) .
TGF-β can induce a proangiogenic environment and stimulate tumor-associated angiogenesis. Elevated expression levels of TGF-β have been linked to increased microvessel density in certain tumor types (63) . The mechanism of angiogenesis stimulated by TGF-β signaling includes the induction of key angiogenic factors, including connective tissue growth factor, vascular endothelial growth factor and insulin-like growth factor-binding protein 7, in epithelial cells and fibroblasts (64, 65) . In addition, TGF-β can induce the expression, secretion and activation of matrix metalloproteinase 2 (MMP2) and MMP9 and down regulate the expression of tissue inhibitor of metalloproteinase in tumor and endothelial cells (66) (67) (68) .
However, TGF-β also has angiostatic functions. For example, in pancreatic cancer and diffuse-type gastric cancer, TGF-β induces the production of thrombospondin1, a potent angiogenic inhibitor, whereas perturbations of TGF-β signaling resulted in accelerated angiogenesis and growth of tumors (69) . Whether TGF-β is angiogenic or angiostaticis is dependent on the cellular context of tumor cells, epithelial cells and the tumor microenvironment.
Conclusion
Several lines of evidence suggest that the TGF-β family is involved in tumor initiation and progression, including cell proliferation, angiogenesis, cancer cell stemness, EMT, invasion and inflammation. TGF-β signaling is complex and mediates pro-and anti-tumoral activities in cancer cells depending on their context in space and time and their microenvironment (52) . It is generally accepted that TGF-β is primarily a tumor suppressor in premalignant cells but functions as a promoter of metastasis in cancer cells (70, 71) . However, the mechanisms underlying the contextual changes in the role of TGF-β remain to be elucidated. Xu et al provided molecular insight into how TGF-β converts from a tumor suppressor to a tumor promoter. It was found that 14-3-3ζ turned off the tumor suppression function of TGF-β by destabilizing p53, a Smad partner in premalignant cells. By contrast, 14-3-3ζ promoted TGF-β-induced distant metastasis by stabilizing Gli family zinc finger 2 (Gli2) and inducing the partnering of Gli2 with Smads in malignant cells (70) . Therefore, the 14-3-3ζ-driven contextual changes of Smad partners from p53 to Gli2 may provide therapeutic targets in TGF-β-mediated cancer progression.
